RWD30 Adverse Event Reporting of Marketed Biosimilar and Biological Monoclonal Antibody Cancer Treatments in the United States
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.2060
https://www.valueinhealthjournal.com/article/S1098-3015(23)02160-5/fulltext
Title :
RWD30 Adverse Event Reporting of Marketed Biosimilar and Biological Monoclonal Antibody Cancer Treatments in the United States
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)02160-5&doi=10.1016/j.jval.2023.03.2060
First page :
Section Title :
Open access? :
No
Section Order :
11372